Amplia Therapeutics Ltd
ASX:ATX

Watchlist Manager
Amplia Therapeutics Ltd Logo
Amplia Therapeutics Ltd
ASX:ATX
Watchlist
Price: 0.13 AUD 1.96% Market Closed
Market Cap: 66.7m AUD

Wall Street
Price Targets

ATX Price Targets Summary
Amplia Therapeutics Ltd

Wall Street analysts forecast ATX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATX is 0.43 AUD with a low forecast of 0.42 AUD and a high forecast of 0.44 AUD.

Lowest
Price Target
0.42 AUD
226% Upside
Average
Price Target
0.43 AUD
230% Upside
Highest
Price Target
0.44 AUD
239% Upside
Amplia Therapeutics Ltd Competitors:
Price Targets
NTLA
Intellia Therapeutics Inc
132% Upside
DVYSR
Devyser Diagnostics AB
53% Upside
VITR
Vitrolife AB
38% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
91% Upside
TNG
Transgene SA
83% Upside
GILD
Gilead Sciences Inc
9% Upside
RCKT
Rocket Pharmaceuticals Inc
133% Upside
ONCO
Oncopeptides AB
1% Downside

Revenue
Forecast

Revenue Estimate
Amplia Therapeutics Ltd

For the last 12 years the compound annual growth rate for Amplia Therapeutics Ltd's revenue is 25%. The projected CAGR for the next 3 years is 39%.

25%
Past Growth
39%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Amplia Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Amplia Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATX's stock price target?
Price Target
0.43 AUD

According to Wall Street analysts, the average 1-year price target for ATX is 0.43 AUD with a low forecast of 0.42 AUD and a high forecast of 0.44 AUD.

What is Amplia Therapeutics Ltd's Revenue forecast?
Projected CAGR
39%

For the last 12 years the compound annual growth rate for Amplia Therapeutics Ltd's revenue is 25%. The projected CAGR for the next 3 years is 39%.

Back to Top